We previously demonstrated that disrupting glutathione metabolism extended survival of mice bearing MYC-driven medulloblastoma orthotopic xenografts, further validating our metabolic findings and showing the value of our metabolic profiling approach [40].The drug difluromethylornithine (DFMO) blocks ODC1 and has had success in high-risk neuroblastoma clinical trials [67,68,69]. The gene discussed is MYC; the disease is neuroblastoma.